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Summary. Background: The endothelial cell protein C receptor
(EPCR) presents protein C to the thrombin:thrombomodulin
complex on the endothelium of large vessels, and enhances the
generation of activated protein C (APC) and activation of
protease-activated receptor-1. A previous report has demon-
strated binding of soluble (s) EPCR to activated neutrophils via
surface proteinase 3 (PR3). Methods: We now report further
characterization of this interaction. Activated neutrophils and
puriﬁedPR3 bothdecreaseendothelialcell(EC) surfaceEPCR,
suggestive of its proteolysis. Results: When added to puriﬁed
recombinant sEPCR, PR3 produced multiple cleavages, with
early products including 20 kDa N-terminal and C-terminal
(after Lys
176) fragments. The binding of active site blocked PR3
tosEPCRwasstudiedbysurfaceplasmonresonance.Estimates
of the KD of 18.5–102 nM were obtained with heterogeneous
binding, suggestive of more than a single interaction
site. Conclusions: This work demonstrates PR3 binding to
and proteolysis of EPCR and suggests a mechanism by which
anticoagulant and cell protective pathways can be down-
regulated during inﬂammation.
Keywords: endothelial cells, EPCR, inﬂammation, neutrophils,
PR3.
Introduction
The protein C anticoagulant pathway is one of the major
coagulation regulatory mechanisms and modulates thrombin
generation by degrading factors (F) Va and VIIIa [1]. On
binding thrombomodulin on the endothelial cell (EC) mem-
brane, thrombin proteolytically activates protein C, whereas its
speciﬁcity for ﬁbrinogen is lost. Activation of protein C is
greatly enhanced in the presence of the endothelial cell protein
C receptor (EPCR) [2–4], a type I transmembrane glycoprotein
related to the CD1/class I major histocompatibility complex
superfamily [5,6], of almost exclusive EC-speciﬁc distribution
[7]. By binding EPCR with high afﬁnity [8,9], protein C is
concentrated on the EC surface and the activation peptide
orientated towards the active site of the thrombomodulin-
thrombin complex, which increases severalfold the generation
of activated protein C (APC) [3].
In addition to its anticoagulant role, EPCR has been shown
to facilitate APC-mediated activation of protease-activated
receptor-1 [10], which stimulates neuroprotective/anti-apoptot-
ic signalling pathways [11]. This activity of EPCR may be
critical in the beneﬁcial clinical effects of APC in the treatment
of severe sepsis, as a sublethal dose of Escherichia coli
administered to baboons became lethal when animals were
simultaneously administered an anti-EPCR monoclonal anti-
body (mAb) that blocks the binding of protein C to EPCR [12].
A soluble form of EPCR (sEPCR) is found in plasma [13],
probably arising from proteolytic cleavage by a metalloprote-
inase [14]. sEPCR can bind to activated neutrophils via
proteinase 3 (PR3) [15], a process partially dependent on the b-
2 integrin Mac-1. PR3 is an elastinolytic neutral serine protease
[16] stored in neutrophil granules which, following cell activa-
tion, is presented on the cell surface. PR3 is best known as the
primary antigen of the antineutrophil cytoplasmic antibodies in
the autoimmune vasculitis Wegeners granulomatosis (WG).
Elevated levels of sEPCR have been found in 24% patients
with active WG [17], which could potentially favor interaction
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tory response [15]. The interaction between EC-anchored
EPCR and neutrophils has not been studied to date. If
membrane EPCR is also able to bind to activated neutrophils,
this would have interesting implications for the pathogenesis of
inﬂammatory reactions because EPCR expression varies
between different vascular beds. We report here further
characterization of the previously reported interaction between
sEPCR and PR3 and demonstrate that sEPCR is rapidly
proteolyzed by PR3. Furthermore, we provide evidence for a
similar effect on EC-bound EPCR by activated neutrophils.
Our data strongly suggest a mechanism for down-regulation of
anticoagulation during inﬂammation.
Methods
Expression and puriﬁcation of soluble EPCR
Recombinant soluble (rs)EPCR incorporating a His tag was
expressed in Pichia pastoris strain X-33 using the EasySelect
Pichia expression kit (Invitrogen, Paisley, UK) broadly as
described [18]. rsEPCR from yeast supernatant was puriﬁed
ﬁrst by afﬁnity chromatography in a HiTrap
TM Chelating
HP column, followed by anion exchange puriﬁcation on a
HiTrap
TM Q HP, mainly as previously described [13]. Purity
was conﬁrmed by sodium dodecylsulfate polyacrylamide gel
electrophoresis (SDS–PAGE) followed by Simply Blue
TM
Safestain (Invitrogen) staining and the presence of rsEPCR
by Western blot analysis with the anti-EPCR RCR-2 mAb
(kindly provided by K. Fukudome, Saga Medical School,
Japan).
Neutrophil isolation
Human neutrophils were isolated from the citrated periph-
eral blood of healthy donors by density gradient centrifu-
gation over Polymorphprep
TM (Axis-shield PoC AS, Oslo,
Norway). The upper (mononuclear) cell layer was discarded.
The lower (neutrophil) layer was collected, washed, and
contaminating erythrocytes lyzed by hypotonic lysis. Neu-
trophils were resuspended in RPMI 1640 medium (Invitro-
gen) supplemented with 100 U mL
)1 penicillin, 100 lgm L
)1
streptomycin, 2 mML -glutamine (Invitrogen) and either 2%
or 10% human male AB serum (Biowest, Ringmer, UK).
Neutrophil purity (> 90%) was assessed by ﬂow cytometry,
and the lack of activation as a result of the isolation process
was conﬁrmed by by luminol-dependent chemiluminescence
as described below.
Flow cytometry
Cells were stained for ﬂow cytometry using a standard
procedure: 1 · 10
5 cells were stained for 30 min at 4  C
with saturating concentrations of the relevant primary or
secondary mAb (predetermined by titration, data not
shown) and appropriate isotype-matched control mAbs of
irrelevant antigenic speciﬁcity. After the ﬁnal wash, cells
were acquired and analyzed on a FACSCalibur (BD
Biosciences, San Jose, CA, USA) using CELLQUEST software
(BD Biosciences). Speciﬁcally, neutrophil purity or presence
was assessed using a combination of forward and side
scatter characteristics, and labelling with mouse antihuman
CD16 PE or CD16 FITC (Caltag, Burlingame, CA, USA).
EPCR expression on EA.hy926 cells, an endothelium-
derived cell line expressing EPCR [19] (a kind gift from
Cora-Jean Edgell, University of North Carolina, Chapel
Hill, NC, USA), was assessed by labelling with the rat
antihuman EPCR mAb RCR-252 (Hycult Biotechnology,
Uden, The Netherlands), or the isotype-matched rat IgG1
control mAb (BD Biosciences), and an antirat FITC-
conjugated secondary mAb (BD Biosciences).
Neutrophil activation
Neutrophil activation as a result of either the isolation
process or incubation with 50 ng mL
)1 phorbol-12-myristate
13-acetate (PMA; Sigma-Aldrich, Gillingham, UK) was
measured by luminol-dependent chemiluminescence. 1 · 10
5
neutrophils were plated in triplicate in a 96-well plate (Costar,
Helena Biosciences, Sunderland, UK) as follows: (i) negative
control, neutrophils alone; (ii) positive control, neutrophils,
5 · 10
)4
M luminol (Sigma-Aldrich) and 50 ng mL
)1 phorbol
12-myristate 13-acetate (PMA, Sigma); (iii) test sample,
neutrophils and 5 · 10
)4
M luminol. The plate was read by a
chemiluminometer (Lucy1; Anthos Labtech, Austria), which
measured emission of light (arbitrary light units) per unit time
at 180-s intervals for 2 h. Light emission was plotted on a light
vs. time graph. The data were analyzed using STINGRAY
software (Dazdaq, Brighton, UK).
Co-culture of EA.hy926 with activated neutrophils
EA.hy926 cells were grown to conﬂuence (1 · 10
6
cells well
)1)o n9 . 6c m
2 diameter six-well plates and incuba-
ted with or without freshly isolated, PMA-activated neu-
trophils (3 · 10
6 well
)1, previously washed to exclude EPCR
cleavage by PMA) for 0, 1, 2 and 24 h. After each time-
point, EC were washed of neutrophils and harvested by
incubation with a non-enzymatic buffer (10 mM EDTA in
phosphate buffered saline, pH 7.4) for 30 min at 37  C. The
surface expression of EPCR on EA.hy926 cells at each time
point after either co-culture with activated neutrophils or
culture alone was measured by ﬂow cytometry using the
anti-EPCR mAb RCR-252, as described above. Where
appropriate, the presence of residual neutrophils was
assessed by staining the EC for CD16.
Incubation of EA.hy926 with puriﬁed PR3
EA.hy926 cells were harvested from conﬂuent cultures as
described above. 1 · 10
6 cells were subsequently incubated
with 100 or 250 nM of PR3 (purity > 95%, Elastin Products
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  2007 The Authors. Journal Compilation   2007 International Society on Thrombosis and HaemostasisCo., Inc., Owensville, MO, USA) in human endothelial-serum
free medium (Invitrogen) supplemented with 20 mM HEPES
(Invitrogen) for 6 h at 37  C. The surface expression of EPCR
on EA.hy926 cells after incubation with PR3 was measured by
ﬂow cytometry using the anti-EPCR mAb RCR-252, as
described above. Dead cells were excluded from the analysis
by staining with propidium iodide immediately prior to
acquisition on the FACSCalibur (BD Biosciences).
Proteolysis of rsEPCR by PR3
PR3, 1 lM,w a si n c u b a t e dw i t h1 0lM rsEPCR at 37  C, either
in HBS-P buffer or in pooled human plasma (Technoclone,
Surrey, UK). Aliquots were taken at 0, 5, 15, 30, 60 and
180 min and the fragmentation of rsEPCR was analyzed by
SDS–PAGE in 16.5% Tris–Tricine gels (Bio-Rad, Hertford-
shire, UK) under reducing conditions, followed by Simply
Blue
TM Safestain staining and Western blotting using anti-His
(C-term) mAb (Invitrogen).
HPLC analysis of rsEPCR cleavage by PR3
rsEPCR (5 lM) was incubated with 0.5 lM PR3 in reaction
buffer (10 mM HEPES, 150 mM NaCl, pH 7.4). Reactions
were stopped after 0, 15, 30, 60, 120, 240 and 390 min by
addition of hundredfold excess of phenyl methyl sulfonyl
ﬂuoride (PMSF) relative to PR3. Samples were separated by
reversed phase chromatography in an A ¨ KTA
TM basic puriﬁer
system (Amersham Biosciences, Little Chalfont, UK) using a
5% to 75% linear gradient of acetonitrile in a 150 mm length
Biobasic C4 column (Thermo Electron Corporation, Basing-
stoke, UK).
Proteomic analysis of rsEPCR cleavage by PR3
rsEPCR (250 pmol) was incubated with 25 pmol PR3 in
5m M ammonium bicarbonate, pH 7.8 for 15 min. Samples
were separated by SDS–PAGE and stained with Simply
Blue
TM Safestain. Gel bands were excised and transferred to
Packard robot, where they were automatically reduced and
carbamidomethylated, following treatment with trypsin, as
described elsewhere [20,21]. The trypsinized samples were
transferred to glass vials for CapLC-MSMS analysis using an
LC packings PepMap column (10 cm · 75 lm, 70 A ˚ ). Sam-
ples were analyzed with MALDI-ToF MS on a MALDI
instrument (Micromass, Altrincham, Cheshire, UK) using
recrystallized alpha-cyano-4-hydroxycinnamic acid as matrix.
MSMS data were obtained on a Micromass QtoF II
instrument, either directly using a nanospray needle or by
capillary LC-MSMS. MS and MSMS data were converted to
Micromass pkl ﬁles for analysis by the MASCOT search
engine (http://www.matrixscience.com) using the non-identi-
cal MSDB protein data base. Individual MSMS spectra were
also analyzed manually. Masses of candidate protein frag-
ments were matched with the EPCR sequence using MICRO-
MASS BIOLYNX software.
Binding afﬁnity of PR3 for rsEPCR
All binding experiments were investigated by SPR using a dual
ﬂowcell BIAcore
  X Biosensor system (Biacore, AB, Uppsala,
Sweden). For direct immobilization analysis, 35 lLo f
60 lgm L
)1 sEPCR solution in 10 mM sodium acetate pH
5.0 was immobilized on one ﬂow cell of a CM-5 sensor chip, to
give a response in resonance units (RU) of 2350. PR3 (1 lM)
was diluted in 50 mM HEPES pH 7.4, 150 mM NaCl (HBS-P,
Biacore) and injected over the sEPCR surface. All subsequent
SPR analyses were performed using a mAb approach as
described elsewhere [22]. Immobilization was performed by
injection of 30 lLo f1 0lgm L
)1 anti-His C-terminal mAb
(Invitrogen) solution in 10 mM sodium acetate pH 5.0 over
both ﬂow cells of a CM-5 sensor chip. A response of between
8000 and 10 000 RU was established. Subsequently, 50 lLo f
rsEPCR diluted in HBS-P was injected and equilibrated over
ﬂow cell 2 only, until the response level was between 850 and
1000 RU. The ﬂow cell without rsEPCR bound was used as a
reference cell. PR3 (0–300 nM) in HBS-P were sequentially
injected over both ﬂow cells at a ﬂow rate of 20 lLm i n
)1 for
200 s. PR3 was allowed to completely dissociate from the
rsEPCR surface before the next PR3 injection. In some
experiments 1 mM PMSF was included in the PR3 dilutions
and in the running buffer to inhibit PR3 activity. Any inﬂuence
of mass transport effects was excluded from the sensograms
based on the equal binding curves obtained when injecting
300 nM PR3 at different ﬂow rates.
Data analysis was performed using the BIAEVALUATION
software 3.0 (Biacore). All data sets were corrected for non-
speciﬁc binding (reference cell subtraction, ﬂowcell 2–ﬂowcell
1) and for refractive index changes (zero subtraction). Kinetics
of PR3 binding to rsEPCR were ﬁtted globally to the
heterogeneous ligand binding model. A second estimation of
the KD was obtained based on the RU values at binding
equilibrium (Req) ﬁtted to the steady state binding model.
Results
Activated neutrophils decrease EPCR on EC
To investigate whether activated neutrophils are able to
interact with EC surface EPCR, freshly isolated neutrophils
(> 90% purity, Fig. 1A), unactivated by the isolation proce-
dure but fully responsive to activation by PMA (Fig. 1B) were
activated with PMA prior to incubation with EA.hy926 cells.
Control EA.hy926 cells were cultured under identical condi-
tions but without neutrophils. In both cases, surface EPCR
expression was measured over time by ﬂow cytometry
(Fig. 1D) with the mAb RCR-252. The EC treated with
activated neutrophils showed a time-dependent reduction of
EPCR expression, observed as a decrease in the mean
ﬂuorescence intensity (MFI) from 49.7 to 28.8, between 0
and 24 h (Fig. 1D, solid thin lines). Similar results were
obtained when EPCR expression was detected by another
antihuman EPCR mAb, RCR-2, recognizing a separate
982 A. Villegas-Mendez et al
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residual neutrophils adherent to the EC was conﬁrmed by ﬂow
cytometry for CD16 FITC(Fig. 1C). WhenEC wereincubated
with non-activated neutrophils, no decrease in surface EPCR
expression was observed (data not shown). These results
suggest that EPCR on the EC is cleaved by a protease present
on the surface of activated neutrophils, although other
mechanisms of down-regulation are not excluded. Of the
proteaserepertoire expressedon activatedneutrophils, PR3 has
previously been shown to interact with sEPCR [15] and is
therefore a candidate cause.
PR3 degrades membrane EPCR
Puriﬁed PR3 from human leukocytes was incubated
with EA.hy926 cells. Cells were incubated with increasing
concentrations of PR3 for 6 h and EPCR detected with RCR-
252. EPCR expression decreased only in cells that had been
incubated with PR3 (Fig. 2) in a time- and dose-dependent
manner. After 6 h, the MFI decreased from 61.0 to 50.6
(100 nM PR3, broken line RCR-252) and 24.5 (250 nM PR3,
thin intact line RCR-252). These data suggest that the loss of
EPCR on EC after neutrophil treatment can be ascribed in part
to the action of PR3.
Proteolysis of rsEPCR by PR3
Cleavage of rsEPCR was followed directly over time by SDS–
PAGE analysis. As shown in Fig. 3A, PR3 rapidly cleaved
rsEPCR at 1:10 molar ratio. Degradation bands of different
Mr (ranging from 2 5t o<1 0k D a )c o u l db es e e na f t e r5m i n
incubation with PR3, which is not observed in the control
C
B
A D
Fig. 1. Loss of endothelial cell protein C receptor (EPCR) expression on endothelial cell (EC) after incubation with activated neutrophils. (A) Purity of
freshly isolated neutrophils. Neutrophil purity, as detected by ﬂow cytometry using a PE-conjugated anti-CD16 monoclonal antibody (mAb) (open
histogram) and an isotype-matched control mAb, was routinely greater than 90%. (B) Activation status of freshly isolated neutrophils. Freshly isolated
neutrophils,tested in triplicate, were unactivated by the isolation procedure(testsample),butcapable ofresponding to the stimulusPMA(positive control),
as measured by luminol-dependent chemiluminescence for 7200 s. The cells were activated with 50 ng mL
)1 PMA for 30 min prior to incubation with
EA.hy926 cells. (C) Eﬃcient removal of activated neutrophils after co-culture with EA.hy926 cells. The lack of contaminating residual neutrophils within
the EC population after co-culture was conﬁrmed by ﬂow cytometry for CD16 FITC (open histogram) and an isotype-matched control mAb (shaded
histogram). The decreased EPCR expressiono b s e r v e di nF i g .1 Dt h e r e f o r er e ﬂ e c t sabona ﬁde decrease in the EC EPCR expression and is not because of a
population of adherent (EPCR-negative) neutrophils. (D) Surface expression of EPCR after incubation with activated neutrophils. EA.hy926 cells were
incubated with or without activated neutrophils for 0, 1, 2 and 24 h. The EPCR expression level on EC after neutrophil treatment (thin solid line) or
medium only treatment (thick solid line) was measured by ﬂow cytometry with the mAb RCR-252 or an isotype-matched rat IgG1 control (discontinuous
lines). The EC treated with activated neutrophils showed a time-dependent reduction of EPCR expression, observed as a decrease in the mean ﬂuorescence
intensity from 49.7 to 28.8 between 0 and 24 h.
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heterogeneity is a result of different glycosylation on the EPCR
molecule). This is indicative of cleavage taking place at several
sites in rsEPCR (Fig. 3A). After 60 min of incubation with
PR3 no intact rsEPCR remained. Accordingly, when a mAb
against the His C-terminus was used in the Western blot
analysis, a progressive degradation of rsEPCR could be
observed. A novel band of 25 kDa was temporarily detected,
again suggesting proteolytic cleavage at several sites (Fig. 3B).
When the experiment was performed in the presence of pooled
human plasma, only a very weak degradation of rsEPCR could
be seen, compatible with the presence of PR3 inhibitors in
plasma, such as a1-antitrypsin [23] (Fig. 3B).
Cleavage of rsEPCR was also investigated by high pressure
liquid chromatography (HPLC) analysis over time after direct
incubation of PR3 with rsEPCR (molar ratio 1:10). At the start
of the incubation (Fig. 4, top panel), rsEPCR eluted at 55% of
the acetonitrile gradient as a single peak and PR3 at 60 and
75% acetonitrile as two peaks. Proteolysis can be observed as
an elution of multiple peaks increasing over time (Fig. 4,
zoomed area), which coincided with the disappearance of the
undigested rsEPCR peak (not shown). These data are indic-
ative of PR3 cleavage at different sites with the subsequent
release of multiple peptides from rsEPCR.
Proteomic analysis of rsEPCR cleavage
rsEPCR was digested with PR3 and the samples run on a non-
reducing SDS–PAGE, followed by Simply Blue
TM Safestain
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Fig. 2. Degradation of membrane endothelial cell protein C receptor
(EPCR) by PR3. EA.hy926 cells were incubated for 6 h with 0 (untreated),
100 and 250 nM PR3. Surface EPCR expression was detected with RCR-
252 by ﬂow cytometry, using an isotype-matched rat IgG1 mAb as a
control. A representative experiment of four independent repeats is shown.
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Fig. 3. Recombinant soluble endothelial cell protein C receptor (rsEPCR)
proteolysis by PR3. (A) sodium dodecylsulfate polyacrylamide gel elec-
trophoresis (SDS–PAGE) analysis. PR3 and rsEPCR (1:10 molar ratio)
w e r ei n c u b a t e di nH B S - Pa t3 7 C for 0, 5, 15, 30 and 60 min and protein
bands resolved by SDS–PAGE under reducing conditions in 16.5% Tris-
Tricine gels. Solid arrows indicate the migration of PR3 and intact
rsEPCR. Dotted arrows indicate degradation products of rsEPCR. (B)
Western blot analysis. rsEPCR was incubated with PR3, as described
above, in HBS-P buﬀer or with pooled human plasma for 0, 15, 30, 60 and
180 min. Samples were subsequently blotted and analyzed with anti-His
(C-term) mAb.
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Fig. 4. High pressure liquid chromatography (HPLC) time-course
analysis of recombinant soluble endothelial cell protein C receptor
(rsEPCR) proteolysis by PR3. rsEPCR (250 pmol) were incubated with
PR3 (25 pmol) and a time-course analysis of cleavage was monitored by
HPLC in a Biobasic C4 column, using a 5–75% acetonitrile gradient. The
s E P C Rp e p t i d e sr e l e a s e du p o nP R 3c l e a v a g eo v e rt i m e( 1 5m i nt o6 . 5h )
are shown in the zoomed chromatograms. O.D.205 nm is expressed in mAU
units; retention volumes are shown in mL.
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(Fig. 5A, lane 2), and the digestion products as a 40 kDa
band (Fig. 5A, lane 3, band 1) and a 20 kDa band (Fig. 5A,
lane 3, band 2). Given the Mr of rsEPCR (45 kDa), another
band of 25 kDa was expected after cleavage with PR3. It is
possible that this band runs simultaneously with the diffuse
band of 20 kDa, or that it gets further proteolyzed into
smaller components and hence is not detected in the gel. All
bands, including PR3 (Fig. 5A, lane 1), undigested rsEPCR
and the two digestion products detected were excised, reduced/
carbamidomethylated and trypsinized under conditions appro-
priate for proteomics analysis. The extracted products were
analyzed by capillary LC-MSMS on a QtoF mass spectrometer
in the survey mode giving both MS and MSMS data. The band
from lane 1 was conﬁrmed to be PR3, while the band from lane
2 matched the sEPCR sequence, with six peptides identiﬁed
providing good coverage of its sequence (Fig. 5B). Peptides
containing predicted post-translational N-linked modiﬁcations
could not be identiﬁed. Fragment 1 of rsEPCR (Fig. 5A, lane
3, band 1) gave similar peptide coverage to sEPCR using the
MASCOT search, except for sequence HISAENTK (176–183
of EPCR, see Fig. 5B, sequence in box and Fig. 5C, region 1),
which was not detected, suggesting cleavage took place after
position 176 of sEPCR (C-terminus cleavage). N-terminal
peptide search (excluding predicted matching against the
sequence containing the signal peptide) on fragment 2 of
rsEPCR (Fig.5A, lane 3, band 2) identiﬁed the sequence
SQDASDGLQR, corresponding to residues 1–10 of sEPCR
(Fig 5B, bold underlined sequence and Fig. 5C, region 2). This
ﬁnding implies that the 20 kDa rsEPCR cleavage product
arises from internal cleavage of sEPCR and contains the
original N-terminus of the protein. This methodology provided
evidence of early proteolysis in adjacent residues of the C-
terminus of sEPCR and an internal region (Fig. 5C).
Afﬁnity of PR3 for rsEPCR
Direct immobilization of ligand molecules was initially
performed to obtain a ﬁrst indication of the binding
between rsEPCR and PR3 by SPR. sEPCR was immobi-
lized onto a sensor chip (Fig. 6A, arrow 1) and 1 lM of
active PR3 injected over the chip (Fig. 6A, arrow 2). Using
this high concentration of PR3, it was apparent the aberrant
dissociation during the association phase (Fig. 6A, arrow 3),
which fell well below (700 RU) the baseline reading
(Fig. 6A, arrow 4) . Interestingly, the injection of protein C
to the rsEPCR exposed to PR3 failed to bind speciﬁcally
(Fig. 6A, arrow 5). To avoid the heterogeneity of direct
coupling and the previously reported loss of sEPCR activity
because of direct binding to artiﬁcial surfaces [24], an
antibody approach was adopted. The anti-His C-terminal
mAb was ﬁrst immobilized onto the surface of a CM5
sensor chip and used to capture rsEPCR expressed in
P. pastoris with a 6-histidine tag at its C-terminus. Non-
speciﬁc binding of PR3 to the control ﬂow cell can be seen
with each PR3 injection (Fig 6B, grey sensorgram). In the
test cell, PR3 could be seen binding to rsEPCR in a
concentration-dependent manner and displacing it from the
anti-His mAb, the latter observed as a drop in the baseline
level of rsEPCR with the sequential injections of PR3
(Fig. 6B, black sensogram). This loss of rsEPCR from the
mAb surface and that observed in the direct immobilization
method (Fig. 6A, arrow 4) were attributed to proteolysis of
rsEPCR by PR3.
To prevent loss of rsEPCR from the sensor chip surface,
experiments were also performed with PMSF inactivated PR3
(Fig. 6C). Use of the 1:1 Langmuir model resulted in poor
ﬁtting, suggesting that the interaction of sEPCR and PR3 does
not follow a simple 1:1 binding. In order to obtain a ﬁrst
estimate of the binding afﬁnity, the Req from each concentra-
tion of PR3 injected over the surface containing rsEPCR, were
used on the steady state ﬁt model (Fig. 6D). Using this model,
the KDfor the interaction of PR3 and rsEPCR was found to be
102 ± 12.6 nM (n = 3). In order to obtain detailed informa-
tion on the association and dissociation phase of the inter-
action, different ﬁtting models were considered. Optimal ﬁtting
was found using the heterogeneous ligand model (Fig. 6C).
This model assumes the ligand (rsEPCR) molecule is hetero-
geneous with regard to analyte (PR3) binding and approxi-
mates the different range of interactions using two sets of rate
constants. Analysis yielded a ka1 of (3.90 ± 0.27) ·
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Fig. 5. Proteomic analysis of recombinant soluble endothelial cell protein
C receptor (rsEPCR) cleavage. (A) rsEPCR (250 pmol) were incubated
with PR3 (25 pmol) for 15 min and electrophoresed on a 16% Tris–
Tricine gel. Protein bands were trypsinized and analyzed by MALDI-ToF.
Lane 1, PR3; lane 2, undigested rsEPCR; lane 3, rsEPCR + PR3,
resulting in bands of 40 kDa (fragment 1) and 20 kDa (fragment 2); lane
4, protein markers. (B) Protein identiﬁcation by MASCOT data base
search using the trypsinized bands from (A). Matching peptides (ﬁrst
residue indicated with asterisk) corresponding to EPCR are highlighted in
grey. The sequence in bold underlined was identiﬁed in fragment 2 by
manual searching ignoring the signal peptide sequence, whereas the
sequence in the box was only identiﬁed in undigested rsEPCR. (C)
Molecular model of full-length EPCR generated by Rasmol 2.6 using the
coordinates provided by Villoutreix et al. [41]. Areas of predicted cleavage
are highlighted as regions 1 (residues HISAENTK, 176–183 of EPCR) and
2 (residues SQDASDGLQR, 1–10 of EPCR).
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5
M
)1 s
)1,akd1 of (1.57 ± 0.23) · 10
)2 s
)1, resulting in a
KD1 of 40.2 ± 4.2 nM and a ka2 of (8.78 ± 3.59) ·
10
4
M
)1 s
)1,akd2 of (1.47 ± 0.08) · 10
)3 s
)1, resulting in a
KD2 of 18.5 ± 6.4 nM (n = 3). Alternative models (heteroge-
neous analyte or conformational change) were excluded as
valid, given the equal dissociation curves obtained after
injection of a high concentration of PR3 (2 lM)a td i f f e r e n t
contact times (2.5 and 5 min), which suggests the presence of
only one population of analyte (data not shown).
Discussion
In addition to its role as an autoantigen in WG, PR3 is known
to have a diverse range of activities in the regulation of
inﬂammation, including degradation of extracellular matrix
proteins [23], potentiation of platelet activation [25] and
processing proinﬂammatory cytokines and receptors to mature
forms (TNF-a,I L - 1 b,T G F - b, IL-18 [26–28]). PR3 has
previously been shown to bind sEPCR on the surface of
activated neutrophils [15]. sEPCR is generated from EC-bound
EPCR by metalloproteolytic release, a highly regulated process
that is sensitive to both coagulation factors (thrombin) and
inﬂammatory mediators (IL-1b) [14]. The signiﬁcance of the
sEPCR-PR3 interaction, and its implications for the function
of sEPCR and of its EC-anchored counterpart have not been
elucidated to date. In this study, we demonstrate that the
binding between rsEPCR and PR3 is a high afﬁnity process of
a complex nature, which results in the proteolytic cleavage of
rsEPCR. We also report for the ﬁrst time, evidence for a similar
interaction between PR3 on activated neutrophils and EC-
anchored EPCR that results in proteolysis of the intact
membrane receptor.
We have shown previously that rsEPCR binding to
protein C is a process characterized by fast association and
dissociation binding rates, resulting in an overall KD of
74.8 nM [22].The binding of rsEPCR to PR3 is also found to
be of high afﬁnity (Fig. 6C), with overall KDs of 40.2 and
18.5 nM. These latter binding interactions may be considered
of doubtful signiﬁcance because the plasma concentration of
sEPCR is 2.5 nM and is elevated only 2- to 5-fold in disease
[13,29]. The demonstration here that incubation of EA.hy926
cells with PMA activated neutrophils resulted in loss of
surface EPCR expression is therefore likely to be of greater
importance. We presume that binding of activated neutroph-
ils to EC via a number of established mechanisms produces
effective high local concentrations of EPCR and PR3
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Fig. 6. SPR analysis of binding between PR3 and rsEPCR (endothelial cell protein C receptor). (A) Loss of protein C binding after rsEPCR exposure to
PR3. (i) Immobilization of rsEPCR in one ﬂow cell of a CM-5 sensor chip (2300 RU), followed by (ii) injection of 1 lMPR3. Proteolysis of rsEPCR can be
appreciated at the end of the association phase (iii) and during the dissociation phase (iv). (v) Injection of 300 nM protein C after sEPCR proteolysis.
(B) Individual ﬂow cell display of PR3 binding to rsEPCR. The anti-His mAb was immobilized on a CM-5 sensor chip (10 000 RU in both ﬂow cells)
to allow the capture of rsEPCR. rsEPCR was injected across ﬂow cell 2 (1000 RU), followed by injection of active PR3 (concentration range from 0 nM
to 200 nM) across both ﬂow cells for 100 s at 20 lLm i n
)1 ﬂow rate. Note that a decrease in the baseline level is only observed in ﬂow cell 2 (black
sensogram), where rsEPCR is immobilized. (C) Binding of phenyl methyl sulfonyl ﬂuoride (PMSF) inactivated PR3 to anti-His captured rsEPCR. The
experiment was performed as described in (B), except for the addition of 1 mM PMSF to inactivate PR3. Increasing concentrations of PMSF inactivated
PR3 (range between 0 nM–300 nM) were injected on the sensor chip surface for 200 s contact time. (D) Binding of PR3 to rsEPCR as assessed by the
steady state model. The Req (180 s of the association phase) from each binding curve represented in (C) were plotted against the corresponding
concentration of PR3 to generate a saturation binding curve. The KD was calculated using the steady state model from the BIAEVALUATION software 3.0.
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The b-2 integrin Mac-1, known to interact with PR3 on the
neutrophil membrane [30], was also found to be partially
involved in the interaction with sEPCR [15]. Thus, an
increase of Mac-1 levels (as reported in the case of active
WG patients [31]) would favor local accumulation of primed
neutrophils on the endothelium at sites of vascular injury.
Although we have not formally investigated the role of Mac-
1 in the binding to EC EPCR, it is plausible that this integrin
further localizes the EPCR interaction with PR3 on the
activated neutrophil surface. However, the potential for the
EPCR interaction with PR3 will vary signiﬁcantly between
different vascular beds because of the variable expression of
EPCR within the vasculature.
PR3 is expressed at detectable levels in the membrane of
resting neutrophils [32,33] and is rapidly up-regulated by
proinﬂammatory mediators, leading to expression of PR3 on
the neutrophil surface. This bound PR3 is resistant to
inhibition by plasma proteinase inhibitors, in marked contrast
to soluble PR3 [33]. Our ﬁnding of plasma inhibition of PR3
mediated sEPCR proteolysis (Fig. 3B) is consistent with this
and is another indicator that the important interaction between
these two molecules is likely to involve their cell surface bound
forms.
The extensive proteolysis of EPCR by PR3 that we have
demonstrated in vitro strongly suggests that a role of PR3 is to
abolish EPCR activity. In support of this hypothesis, SPR
experiments indicate that sEPCR does not bind protein C after
proteolysis by PR3 (Fig. 6A). Moreover, the cleavage appeared
to be speciﬁc for EPCR, as PR3 failed to cleave immobilized
anti-His mAb in the control ﬂow cell (see Fig. 6B, grey
sensogram) and other mAbs or control proteins (thrombin)
used during the SPR optimization process (data not shown).
Such action of PR3 from activated neutrophils on EC-
anchored EPCR is likely to be of pathophysiological import-
ance. In addition to its role in regulation of coagulation
activity, APC inhibits leukocyte adhesion to vascular EC and
proinﬂammatory cytokine release from monocytes [34], redu-
ces accumulation of neutrophils in rat lungs [35] and protects
baboons from E. coli-induced sepsis. At the cell molecular
level, APC modulates patterns of gene expression of the anti-
inﬂammatory, cell survival and apoptosis pathways in EC [36].
In addition, other mechanisms in combination with proteolysis
could account for the decreased EPCR levels. EC can
internalize PR3 and activate proapoptotic signaling pathways
[37–39] in response to vascular injury [40]. It can be hypothes-
ized that the high afﬁnity of EPCR for PR3 on the EC surface
might contribute to localizing activated neutrophils in the
damaged area and trigger proteolysis of EPCR, facilitating
internalization of PR3. Depletion of EPCR on the EC surface
during acute inﬂammation might therefore accentuate the
inﬂammatory process.
The ﬁnding of cleavage at the C-terminus of sEPCR between
Lys
175 and His
176 (Fig. 5B), suggests that at least one of the
initial binding sites of PR3 on sEPCR might be located in its C-
terminal region. This is compatible with protein C or APC not
affecting signiﬁcantly the sEPCR-PR3 interaction [15]. The
multiple cleavage sites demonstrated bySDS–PAGE (Fig. 3A),
HPLC (Fig. 4) and proteomic analysis (Fig. 5A,B) suggest a
complex interaction between sEPCR and PR3, observed also
by SPR (Fig. 6C), with PR3 binding on different regions of
sEPCR. This is therefore an unlikely target for potential
pharmacological inhibition.
We have conﬁrmed a high afﬁnity interaction between the
neutrophil protease PR3 and the EPCR, which results in the
proteolytic degradation of the receptor. Further experiments
have shown that in vivo this is likely to be mediated by cellular
interaction involving the surface bound forms of the molecules.
Degradation of EPCR with consequent loss of APC generation
is likely to contribute to the already known proinﬂammatory
roles of PR3.
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